Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells

Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies

(2015) Francesco Caiazza et al.   Biomarkers in Medicine

Targeting PI3K/Akt/mTOR Cascade: The Medicinal Potential, Updated Research Highlights and Challenges Ahead

(2013) X. Ma et al.   CURRENT MEDICINAL CHEMISTRY

ADAM-17: a novel therapeutic target for triple negative breast cancer

(2012) P. M. McGowan et al.   ANNALS OF ONCOLOGY

A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes

(2012) B Dutta et al.   BRITISH JOURNAL OF CANCER

The evolving landscape of protein kinases in breast cancer: Clinical implications

(2012) Alberto Ocaña et al.   CANCER TREATMENT REVIEWS

Three-dimensional cell culture: the missing link in drug discovery

(2012) Susan Breslin et al.   DRUG DISCOVERY TODAY

Targeted therapy for triple-negative breast cancer: Where are we?

(2012) Michael J. Duffy et al.   INTERNATIONAL JOURNAL OF CANCER

Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

(2012) Johannes M. Heuckmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo

(2012) Frances M. Richards et al.   PLoS One

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

(2011) D. M. Collins et al.   ANNALS OF ONCOLOGY

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR

(2011) M. P. Roberti et al.   BREAST CANCER RESEARCH AND TREATMENT

EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects

(2011) Jean-Charles Soria et al.   CANCER TREATMENT REVIEWS

Inflammatory Skin and Bowel Disease Linked toADAM17Deletion

(2011) Diana C. Blaydon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cross-domain inhibition of TACE ectodomain

(2011) C. J. Tape et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Developments in three-dimensional cell culture technology aimed at improving the accuracy ofin vitroanalyses

(2010) Daniel J. Maltman et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

ADAM-17: the enzyme that does it all

(2010) Monika Gooz   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

The role of ADAMs in disease pathophysiology

(2009) Michael J. Duffy et al.   CLINICA CHIMICA ACTA

Role of ADAMs in Cancer Formation and Progression

(2009) M. J. Duffy et al.   CLINICAL CANCER RESEARCH

ADAMs 10 and 17 Represent Differentially Regulated Components of a General Shedding Machinery for Membrane Proteins Such as Transforming Growth Factor α, L-Selectin, and Tumor Necrosis Factor α

(2009) Sylvain M. Le Gall et al.   MOLECULAR BIOLOGY OF THE CELL

ADAM-17 predicts adverse outcome in patients with breast cancer

(2008) P. M. McGowan et al.   ANNALS OF ONCOLOGY

Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity

(2008) Linda Hughes et al.   CLINICAL & EXPERIMENTAL METASTASIS